このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Clene マネジメント

マネジメント基準チェック /34

Clene'sの CEO はRob Etheringtonで、 Apr2013年に任命され、の在任期間は 11.17年です。の年間総報酬は$ 1.71Mで、 38.3%給与と61.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.073%を直接所有しており、その価値は$ 35.23K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と3.5年です。

主要情報

Rob Etherington

最高経営責任者

US$1.7m

報酬総額

CEO給与比率	38.3%
CEO在任期間	11.4yrs
CEOの所有権	0.5%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Clene の収益と比較して、Rob Etherington の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$2m	US$654k	-US$50m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$2m	US$561k	-US$30m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	US$15m
Mar 31 2022	n/a	n/a	US$17m
Dec 31 2021	US$5m	US$510k	-US$10m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$55m
Dec 31 2020	US$498k	US$335k	-US$19m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$510k	US$335k	-US$16m
Dec 31 2018	US$465k	US$335k	-US$12m

報酬と市場: Robの総報酬 ($USD 1.71M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Rob Etherington (57 yo)

11.4yrs

在職期間

US$1,706,605

報酬

Mr. Robert Etherington, also known as Rob, MBA, serves as Chief Executive officer, President and Director at Clene Nanomedicine, Inc. He serves as President, Chief Executive Officer and Director at Clene...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Etherington	CEO, President & Director	11.4yrs	US$1.71m	0.50% $ 154.4k
Morgan Brown	Chief Financial Officer	2.6yrs	US$993.70k	0% $ 0
Mark Mortenson	Chief Science Officer	no data	US$1.38m	0.13% $ 40.7k
Jerry Miraglia	General Counsel & Corporate Secretary	no data	データなし	データなし
Michael Hotchkin	Chief Development Officer	no data	データなし	データなし
Mary Mcneil	Head of Human Resources	no data	データなし	データなし
Benjamin Greenberg	Head of Medical	1.5yrs	データなし	データなし

2.6yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: CLNNの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Etherington	CEO, President & Director	11.4yrs	US$1.71m	0.50% $ 154.4k
David Matlin	Independent Chairman of the Board	3.8yrs	US$99.65k	5.56% $ 1.7m
Reed Wilcox	Independent Director	11.5yrs	データなし	0.44% $ 138.6k
Jonathon Gay	Independent Director	3.8yrs	US$67.50k	0.13% $ 42.0k
Alison Mosca	Independent Director	5yrs	US$82.64k	3.66% $ 1.1m
Arjun Desai	Independent Director	less than a year	US$31.09k	0.013% $ 3.9k
Shalom Jacobovitz	Independent Director	11.5yrs	US$81.14k	0.058% $ 18.1k
Matthew Kiernan	Independent Director	less than a year	US$29.59k	0.0066% $ 2.1k
Vallerie McLaughlin	Independent Director	3.1yrs	US$65.63k	0% $ 0

3.8yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: CLNNの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Clene マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Clene Inc., Annual General Meeting, May 29, 2024

Independent Chairman of the Board recently bought US$103k worth of stock

High number of new directors

Clene Inc. Announces Executive Changes

Independent Director recently bought US$253k worth of stock

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Recent updates

Price target decreased by 13% to US$48.00

Second quarter 2024 earnings released: US$1.06 loss per share (vs US$5.84 loss in 2Q 2023)

Price target decreased by 8.8% to US$91.25

New major risk - Share price stability

New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

Clene Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2) for Continued Listing on Nasdaq

Consensus revenue estimates increase by 16%

Clene Inc. and Clene Nanomedicine Inc. Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS

Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome

Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg

Consensus revenue estimates fall by 30%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver

Clene Inc., Annual General Meeting, May 29, 2024

Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs

Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement

Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial

Price target decreased by 11% to US$5.00

Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases

Independent Chairman of the Board recently bought US$103k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Revenue and earnings growth

High number of new directors

Clene Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%, EPS downgraded

Price target decreased by 13% to US$5.83

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

New minor risk - Share price stability

Independent Director recently bought US$253k worth of stock

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Price target decreased by 20% to US$6.71

Consensus revenue estimates increase by 21%

New major risk - Shareholder dilution

Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial

Clene Inc. has completed a Follow-on Equity Offering.

Clene Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 27%

Consensus revenue estimates decrease by 53%, EPS upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 10% to US$8.57

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$9.57

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity

Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board recently bought US$2.9m worth of stock

High number of new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$10.57

Clene Inc. and Clene Nanomedicine Inc. Reports Topline Results Demonstrating Survival Signal for Cnm-Au8 in Healey Als Platform Trial

Investor sentiment deteriorated over the past week

Clene slips 13% as lead asset fails in ALS study

Clene Inc. and its Wholly Owned Subsidiary Clene Nanomedicine Inc. Present Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Consensus estimates of losses per share improve by 12%

Independent Director recently bought US$183k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

Investor sentiment deteriorated over the past week

Consensus forecasts updated

CEO, President & Director notifies of intention to sell stock

Clene ALS therapy gets EMA panel backing for orphan drug status

Clene Inc Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

マネジメント基準チェック /34